Belvedere Trading
RPTX

Belvedere Trading’s Repare Therapeutics RPTX Stock Holding History

Belvedere Trading’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,189
Closed -$74.8K – 968
2023
Q3 		$74.8K Buy
+6,189
New +$63.9K ﹤0.01% 372

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Belvedere Trading's RPTX Position: Q4 2023 in Review

Belvedere Trading sold out of Repare Therapeutics (RPTX) in Q4 2023, closing a stake of 6,189 shares — an estimated $74.8K sold.

Belvedere Trading first reported a position in RPTX in Q3 2023 and held it in 1 quarter. The position peaked at $74.8K in Q3 2023. 69 funds tracked by Wall St. Rank hold RPTX as of Q4 2023.

  • Belvedere Trading reported no remaining Repare Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 6,189 Repare Therapeutics shares in Q4 2023, an estimated $74.8K.
  • Belvedere Trading first reported a position in Repare Therapeutics in Q3 2023 and held it in 1 quarter.
  • Belvedere Trading's Repare Therapeutics position peaked at $74.8K in Q3 2023.
  • 69 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.